These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 6765966)
41. Analysis of immune deviation elicited by antigens injected into the subretinal space. Wenkel H; Streilein JW Invest Ophthalmol Vis Sci; 1998 Sep; 39(10):1823-34. PubMed ID: 9727405 [TBL] [Abstract][Full Text] [Related]
42. Malignant cell arrest in thymus and spleen of mice bearing transplanted tumors. Haran-Ghera N; Krauthgamer R; Peled A J Immunol; 1981 Apr; 126(4):1241-4. PubMed ID: 6782158 [TBL] [Abstract][Full Text] [Related]
43. Regulation of immunity toward allogeneic tumors in mice. I. Effect of antiserum fractions on tumor growth. Takasugi M; Hildemann WH J Natl Cancer Inst; 1969 Oct; 43(4):843-56. PubMed ID: 5344181 [No Abstract] [Full Text] [Related]
44. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Chen L; McGowan P; Ashe S; Johnston JV; Hellström I; Hellström KE Cancer Res; 1994 Oct; 54(20):5420-3. PubMed ID: 7522958 [TBL] [Abstract][Full Text] [Related]
45. H-2-linked resistance to mastocytoma in male mice: immune response to a histocompatibility antigen on the X chromosome. Kwak LW; Kucuk O; Melvold RW; Williams RM Science; 1983 May; 220(4600):959-61. PubMed ID: 6405481 [TBL] [Abstract][Full Text] [Related]
46. Anti-estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes. Nagy E; Baral E; Kangas L; Berczi I Anticancer Res; 1997; 17(2A):1083-8. PubMed ID: 9137453 [TBL] [Abstract][Full Text] [Related]
47. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants. Maryanski JL; Marchand M; Uyttenhove C; Boon T Int J Cancer; 1983 Jan; 31(1):119-23. PubMed ID: 6187698 [TBL] [Abstract][Full Text] [Related]
48. [Preparation and characterization of human colon tumor-associated antigen and its clinical significance]. Liu XY; Yao XL; Song Y; Liu XY; Zhang P; Xu ZS; Song LH Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Apr; 23(4):335-7. PubMed ID: 17428389 [TBL] [Abstract][Full Text] [Related]
49. The use of P815: a warning. Dullens HF; Den Otter W Immunol Lett; 1983 Jun; 6(6):309-10. PubMed ID: 6414945 [TBL] [Abstract][Full Text] [Related]
50. Experimental models with possible implications for the role of HLA in malignancy. Williams RM Prog Clin Biol Res; 1977; 16():21-8. PubMed ID: 410036 [No Abstract] [Full Text] [Related]
51. The effect of tranexamic acid on growth and spread of an experimental tumor model. Teodorczyk-Injeyan J; Falk R; Ng RW; Kellen JA Res Commun Chem Pathol Pharmacol; 1983 Mar; 39(3):515-8. PubMed ID: 6407075 [TBL] [Abstract][Full Text] [Related]
52. Purification of antigens from urine of a sarcoma patient by affinity chromatography. Huth JF; Gupta RK; Morton DL J Surg Oncol; 1981; 18(3):237-47. PubMed ID: 7311552 [No Abstract] [Full Text] [Related]
53. [Influence of vesicular stomatitis virus upon growth and immunogenicity of a transplantable murine tumour]. Bandlow G; Schlemminger B Zentralbl Bakteriol Orig A; 1974; 227(1-4):414-5. PubMed ID: 4154621 [No Abstract] [Full Text] [Related]
54. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. Fioretti F; Fradelizi D; Stoppacciaro A; Ramponi S; Ruco L; Minty A; Sozzani S; Garlanda C; Vecchi A; Mantovani A J Immunol; 1998 Jul; 161(1):342-6. PubMed ID: 9647242 [TBL] [Abstract][Full Text] [Related]
55. Cytotoxic activity of gallic acid against liver metastasis of mastocytoma cells P-815. Ohno T; Inoue M; Ogihara Y Anticancer Res; 2001; 21(6A):3875-80. PubMed ID: 11911262 [TBL] [Abstract][Full Text] [Related]
56. Failure of anti-T cell monoclonal antibodies to prevent acute tumor allograft rejection is associated with their inability to deplete or inactivate T cells at the site of rejection. Rakhmilevich AL Transplantation; 1994 Jul; 58(1):72-80. PubMed ID: 7913562 [TBL] [Abstract][Full Text] [Related]
57. Anti-tumor effects of an antiserum raised in syngeneic mice to a tumor-specific T suppressor factor. Maier T; Levy JG Cancer Immunol Immunother; 1982; 13(2):134-9. PubMed ID: 6819080 [TBL] [Abstract][Full Text] [Related]
58. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. Fallarino F; Uyttenhove C; Boon T; Gajewski TF J Immunol; 1996 Feb; 156(3):1095-100. PubMed ID: 8557984 [TBL] [Abstract][Full Text] [Related]
59. Altered immunologic responsiveness in mastocytoma-bearing mice. Kamo I; Patel C; Friedman H J Natl Cancer Inst; 1976 Feb; 56(2):333-8. PubMed ID: 815558 [TBL] [Abstract][Full Text] [Related]
60. Demonstration and characterization of polyoma-tumor-associated antigenic components using preparative and analytical polyacrylamide gel electrophoresis. Porwit-Bóbr Z; Pawełek J; Górka M Arch Immunol Ther Exp (Warsz); 1982; 30(1-2):11-6. PubMed ID: 6184028 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]